Zobrazeno 1 - 10
of 3 493
pro vyhledávání: '"Original Reports"'
Autor:
Joyce F. Liu, Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher, David Cella, William P. Tew, Noelle G. Cloven, Carolyn Y. Muller, David P. Bender, Richard G. Moore, David P. Michelin, Steven E. Waggoner, Melissa A. Geller, Keiichi Fujiwara, Stacy D. D'Andre, Michael Carney, Angeles Alvarez Secord, Katherine M. Moxley, Michael A. Bookman
Publikováno v:
J Clin Oncol
PURPOSE Platinum-based chemotherapy is the standard of care for platinum-sensitive ovarian cancer, but complications from repeated platinum therapy occur. We assessed the activity of two all-oral nonplatinum alternatives, olaparib or olaparib/cediran
Autor:
David T. Teachey, Meenakshi Devidas, Brent L. Wood, Zhiguo Chen, Robert J. Hayashi, Michelle L. Hermiston, Robert D. Annett, J. Hunter Archer, Barbara L. Asselin, Keith J. August, Steve Y. Cho, Kimberly P. Dunsmore, Brian T. Fisher, Jason L. Freedman, Paul J. Galardy, Paul Harker-Murray, Terzah M. Horton, Alok I. Jaju, Allison Lam, Yoav H. Messinger, Rodney R. Miles, Maki Okada, Samir I. Patel, Eric S. Schafer, Tal Schechter, Neelam Singh, Amii C. Steele, Maria Luisa Sulis, Sarah L. Vargas, Stuart S. Winter, Charlotte Wood, Patrick Zweidler-McKay, Catherine M. Bollard, Mignon L. Loh, Stephen P. Hunger, Elizabeth A. Raetz
Publikováno v:
J Clin Oncol
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 40, iss 19
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 40, iss 19
PURPOSE To improve the outcomes of patients with T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LL), the proteasome inhibitor bortezomib was examined in the Children's Oncology Group phase III clinical trial AALL1231, which
Autor:
Robert J. Huang, Nicole Sung-Eun Kwon, Yutaka Tomizawa, Alyssa Y. Choi, Tina Hernandez-Boussard, Joo Ha Hwang
Publikováno v:
JCO Clin Cancer Inform
PURPOSE Noncardia gastric cancer (NCGC) is a leading cause of global cancer mortality, and is often diagnosed at advanced stages. Development of NCGC risk models within electronic health records (EHR) may allow for improved cancer prevention. There h
Autor:
Charlotta Lindvall, Chih-Ying Deng, Nicole D. Agaronnik, Anne Kwok, Soujanya Samineni, Renato Umeton, Warren Mackie-Jenkins, Kenneth L. Kehl, James A. Tulsky, Andrea C. Enzinger
Publikováno v:
JCO Clin Cancer Inform
PURPOSE Symptoms are vital outcomes for cancer clinical trials, observational research, and population-level surveillance. Patient-reported outcomes (PROs) are valuable for monitoring symptoms, yet there are many challenges to collecting PROs at scal
Autor:
Sunny Guin, Tomi Jun, Vaibhav G. Patel, Kristin L. Ayers, Matthew Deitz, Yuqin Cai, Xiang Zhou, Che-Kai Tsao, William K. Oh, Rong Chen, Bobby C. Liaw
Publikováno v:
JCO Clin Cancer Inform
PURPOSE Data quality and standardization remain a challenge when analyzing real-world clinical data. We built a clinical research database, using machine learning and natural learning processing, and investigated factors influencing testosterone reco
Autor:
Edmund M. Qiao, Alexander S. Qian, Vinit Nalawade, Rohith S. Voora, Nikhil V. Kotha, Lucas K. Vitzthum, James D. Murphy
Publikováno v:
JCO Clin Cancer Inform
PURPOSE Older hospitalized cancer patients face high risks of hospital mortality. Improved risk stratification could help identify high-risk patients who may benefit from future interventions, although we lack validated tools to predict in-hospital m
Autor:
Silvia Maria Prioli De Souza Sabino, David J. Sheedy, Gigin Lin, Constance D. Lehman, Thiago Buosi Silva, Bruno Souza, Siddharth Satuluru, Sharon Handelman-Gotlib, Michal Guindy, Kevin S. Hughes, Peter G. Mikhael, Bipin Karunakaran, Regina Barzilay, Lisa M Matthis, Karen E Hegarty, Judy Wawira Gichoya, Renato F Caron, Tal Patalon, Adam Yala, Thomas Kim, Hari Trivedi, Fredrik Strand, Maria C Evangelista, Imon Banerjee, Edmundo Carvalho Mauad
Publikováno v:
J Clin Oncol
PURPOSE Accurate risk assessment is essential for the success of population screening programs in breast cancer. Models with high sensitivity and specificity would enable programs to target more elaborate screening efforts to high-risk populations, w
Autor:
Senthil, Damodaran, Fengmin, Zhao, Dustin A, Deming, Edith P, Mitchell, John J, Wright, Robert J, Gray, Victoria, Wang, Lisa M, McShane, Larry V, Rubinstein, David R, Patton, P Mickey, Williams, Stanley R, Hamilton, Jennifer M, Suga, Barbara A, Conley, Carlos L, Arteaga, Lyndsay N, Harris, Peter J, O'Dwyer, Alice P, Chen, Keith T, Flaherty
Publikováno v:
J Clin Oncol
Activating mutations in PIK3CA are observed across multiple tumor types. The NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted therapies on the basis of matching genomic alterations. Arm Z1F evaluated copanlisib,
Autor:
Ho, Alan L., Dedecjus, Marek, Wirth, Lori J., Tuttle, R. Michael, Inabnet, William B., Tennvall, Jan, Vaisman, Fernanda, Bastholt, Lars, Gianoukakis, Andrew G., Rodien, Patrice, Paschke, Ralf, Elisei, Rossella, Viola, David, So, Karen, Carroll, Danielle, Hovey, Tina, Thakre, Bhavana, Fagin, James A.
Publikováno v:
J Clin Oncol
PURPOSE Selumetinib can increase radioactive iodine (RAI) avidity in RAI-refractory tumors. We investigated whether selumetinib plus adjuvant RAI improves complete remission (CR) rates in patients with differentiated thyroid cancer (DTC) at high risk
Autor:
Marjory Charlot, Jacob Newton Stein, Emily Damone, Isabella Wood, Moriah Forster, Stephanie Baker, Marc Emerson, Cleo Samuel-Ryals, Christina Yongue, Eugenia Eng, Matthew Manning, Allison Deal, Samuel Cykert
Publikováno v:
J Clin Oncol
PURPOSE Timely lung cancer surgery is a metric of high-quality cancer care and improves survival for early-stage non–small-cell lung cancer. Historically, Black patients experience longer delays to surgery than White patients and have lower surviva